SCHEMBL521646

SCHEMBL521646

CSc1ncc2ccc(-c3ncccn3)n2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.34
INSR P06213 2/20 0.33
ALK Q9UM73 2/20 0.33
HTT P42858 1/20 0.33
PTK2 Q05397 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.32
RPS6KA5 O75582 1/20 0.32
DYRK3 O43781 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521927 0.84 LMNA (0.41) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL519714 0.81 KDM4E (0.52) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL521268 0.80 KDM4E (0.32) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL520377 0.78 JAK2 (0.44) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL522337 0.78 JAK2 (0.46) JAK2INSRALKPTK2DYRK3
SCHEMBL522182 0.78 JAK2 (0.41) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL520259 0.77 EGLN2 (0.40) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL519978 0.77 MAPK1 (0.44) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL521590 0.77 EGLN2 (0.40) JAK2KDM4EALDH1A1HPGDMAPT
SCHEMBL521486 0.77 JAK2 (0.39) JAK2KDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 JAK2 1/4885KDM4E 192/4885ALDH1A1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.